More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$18.13B
EPS
18.02
P/E ratio
35.8
Price to sales
6.14
Dividend yield
--
Beta
1.122834
Previous close
$653.94
Today's open
$653.94
Day's range
$644.30 - $656.56
52 week range
$373 - $693.97
show more
CEO
August J. Troendle
Employees
5900
Headquarters
Cincinnati, OH
Exchange
Nasdaq Global Select
Shares outstanding
27971686
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?
Here is how Medpace (MEDP) and Atea Pharmaceuticals, Inc. (AVIR) have performed compared to their sector so far this year.
Zacks Investment Research • Nov 13, 2026

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks Investment Research • Nov 11, 2026

Madison Mid Cap Fund Q3 2026 Portfolio Activity
The Madison Mid Cap Fund (Class I) returned -2.09% in the third quarter, compared to the Russell Midcap Index return of -3.00%. The top five contributors for the quarter were Gartner, Medpace Holdings, Ross Stores, Revvity, and Waters Corporation. The bottom five detractors for the quarter were MKS, Floor & Decor Holdings, Carlisle Companies, Moelis and Co., and Glacier Bancorp.
Seeking Alpha • Nov 6, 2026

CON vs. MEDP: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research • Nov 2, 2026

Medpace (MEDP) is a Great Momentum Stock: Should You Buy?
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research • Oct 30, 2026

Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Research • Oct 29, 2026

Here's Why Medpace (MEDP) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research • Oct 26, 2026

All You Need to Know About Medpace (MEDP) Rating Upgrade to Buy
Medpace (MEDP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research • Oct 26, 2026

Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Zacks Investment Research • Oct 26, 2026

Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate
Medpace Holdings is downgraded from "Buy" to "Hold" due to decelerating growth metrics and underwhelming forward guidance. Q3 2026 Net New Business Awards rose just 10.6%, a sharp slowdown from Q2's 28.2% growth, signaling weaker contract momentum. Revenue growth in Q3 2026 was 8.5% to $716M, below the prior quarter's 17.2% pace and only modestly above consensus.
Seeking Alpha • Oct 25, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Medpace Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.